4.6 Article

Messages from the second International Conference on Clinical Metagenomics (ICCMg2)

期刊

MICROBES AND INFECTION
卷 20, 期 4, 页码 222-227

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.micinf.2018.02.005

关键词

Metagenomics; Next-generation sequencing; Microbiota; Bioinformatics; Conference report

资金

  1. American Society of Microbiology [ASM]
  2. Campus Biotech Foundation
  3. Federation of European Microbiology Societies [FEMS]
  4. Geneva University Hospitals [HUG]
  5. Swiss National Fund [31CO30_175439]
  6. Becton-Dickinson
  7. Danone
  8. Ofxord Nanopore Technologies
  9. Roche
  10. bioMerieux
  11. Fasteris
  12. Ferring
  13. Institut Merieux
  14. MaaT Pharma
  15. Nestle
  16. Pathoquest

向作者/读者索取更多资源

Clinical metagenomics (CMg) refers to as the application of metagenomic sequencing of clinical samples in order to recover clinically-relevant information. Due to the increasing access to next-generation sequencing (NGS) facilities, CMg is a gast-growing field. In this context, we held the second International Conference on Clinical Metagenomics (ICCMg2) in Geneva in October 2017. During the two days of the conference, several aspects of CMg were addressed, which we propose to summarize in the present manuscript. Besides, we also discuss the evolution of CMg from the last conference held in 2016. In brief, many technical issues related to CMg are expected to be successfully addressed in the coming years. Conversely, assessing the clinical value of CMg, implementing a quality process, storage of data and the ethics of CMg are emerging challenges. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据